Post-investment value creation in medtech is complex.
Portfolio companies struggle with prioritising R&D, aligning innovation to market needs, and making capital-efficient development decisions. Corporate investors face fragmented innovation efforts and unclear strategic ROI.
Innovation and R&D strategy
We support investors and corporate venture arms with portfolio-level and asset-level innovation strategy.
This includes R&D prioritisation, platform vs product decisions, pipeline roadmapping, and alignment of technical development with commercial and exit objectives.
Our work bridges science, engineering, and business �" ensuring innovation strategy translates into investable outcomes.
Focused Value Creation
R&D and innovation prioritised around what drives enterprise value.
Capital-Efficient Development
Clear trade-offs between platforms, products, and timelines.
Lab-to-Exit Alignment
Technical strategy aligned with market access, scale-up, and exit pathways.Start a strategy conversation
Book a free consultation to explore how a disciplined strategy can unlock portfolio value.
Not sure which of our investor services fits your requirements? Book a consultation to talk through your goals and constraints.
